Verteporfin

129497-78-5

C41H42N4O8

DMSO : 8 mg/mL (11.13 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble)

Stem Cell/Wnt; Autophagy

Verteporfin is a benzoporphyrin derivative monoacid ring A, and can inhibit the activity of YAP. In Vitro: Verteporfin is specifically selected by PDX-cell screening. The concentrations to cause 50% growth inhibition (GI₅₀) for PhLO, PhLH, and PhLK are 228 nM, 395 nM, and 538 nM, respectively, whereas GI₅₀ for ALL-1, TCC-Y/sr, and NPhA1 are 3.93 uM, 2.11 uM, and 5.61 uM, respectively. GSH significantly reduces the sensitivity of 2 out of 3 PDX cells to verteporfin. Verteporfin reduces the mitochondrial membrane potential in PDX cells^[1]. Verteporfin reduces the PTX-resistance on HCT-8/T cells by inhibiting YAP expression and combination therapy with verteporfin and paclitaxel (PTX) shows synergism on inhibition of YAP and cytotoxicity to HCT-8/T^[2]. In Vivo: Verteporfin (10 mg/kg, c.s.c.) and dasatinib significantly reduces the leukemia cell ratio, and combined therapy further reduced the number of leukemia cells in the spleen^[1].